Acute effects of acylated and unacylated ghrelin on total and high molecular weight adiponectin inmorbidly obese subjects

What Was Tested

The paper reports a study of Ghrelin, published as a randomized controlled trial.

Energy homeostasis and body weight are regulated by a highly complex network involving the brain, the digestive tract, and white adipose tissue (WAT).

Knowledge about signaling pathways connecting digestive tract and WAT is limited.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Ghrelin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Ghrelin could be set against what happens without it.

In the crossover set-up each of the participants took both Ghrelin and the comparison in turn, acting as their own control.

Study medication was administered as single iv bolus injections at 09:00 h after an overnight fast.

What Was Measured

PubMed files the paper under topics including Acylation, Adiponectin, Blood Glucose, Ghrelin, Insulin, Insulin Resistance and Molecular Weight.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Ghrelin compound page, all human trials.